Arbutus Biopharma (ABUS) News Today $3.46 -0.09 (-2.54%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Arbutus Biopharma (NASDAQ:ABUS) Shares Gap Down - Here's WhyArbutus Biopharma (NASDAQ:ABUS) Shares Gap Down - Should You Sell?December 16 at 12:56 PM | marketbeat.comCharles Schwab Investment Management Inc. Grows Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)Charles Schwab Investment Management Inc. raised its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 218.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,212,246 shares of the biopharmaDecember 14, 2024 | marketbeat.comHere’s Why Arbutus (ABUS) Surged in Q3December 6, 2024 | msn.comInvestor urges Bucks County firm Arbutus to seek partner over sale of stockDecember 5, 2024 | bizjournals.comWhitefort Capital Sends Letter To Arbutus Board; Requests MeetingDecember 3, 2024 | markets.businessinsider.comWhitefort Capital sends letter to Arbutus Biopharma board of directorsDecember 3, 2024 | markets.businessinsider.comArbutus Biopharma Co. (NASDAQ:ABUS) Short Interest UpdateArbutus Biopharma Co. (NASDAQ:ABUS - Get Free Report) was the recipient of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 6,060,000 shares, a decline of 7.3% from the October 31st total of 6,540,000 shares. Based on an average daily volume of 1,150,000 shares, the days-to-cover ratio is currently 5.3 days.December 2, 2024 | marketbeat.comJoin Arbutus Biopharma for Virtual Fireside Chat!November 30, 2024 | msn.comArbutus Biopharma Highlights Hepatitis B Treatment AdvancesNovember 26, 2024 | markets.businessinsider.comArbutus to Participate in H.C Wainwright @ Home Virtual Fireside ChatNovember 26, 2024 | globenewswire.comArbutus Biopharma (NASDAQ:ABUS) Stock Quotes, Forecast and News SummaryNovember 20, 2024 | benzinga.comArbutus Biopharma (NASDAQ:ABUS) Earns "Buy" Rating from Chardan CapitalChardan Capital restated a "buy" rating and set a $5.00 price objective on shares of Arbutus Biopharma in a report on Wednesday.November 20, 2024 | marketbeat.comArbutus Biopharma’s Promising Clinical Trial Results Lead to Buy RatingNovember 20, 2024 | markets.businessinsider.comArbutus Biopharma price target raised to $5 from $4.50 at ChardanNovember 20, 2024 | markets.businessinsider.comArbutus Biopharma’s Promising Breakthrough in Chronic Hepatitis B Treatment Justifies Buy RatingNovember 18, 2024 | markets.businessinsider.comArbutus Biopharma: Promising Developments and Positive Outlook Boost Buy RatingNovember 18, 2024 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for Arbutus Biopharma (NASDAQ:ABUS)HC Wainwright restated a "buy" rating and issued a $5.00 price target on shares of Arbutus Biopharma in a research note on Monday.November 18, 2024 | marketbeat.comArbutus Biopharma’s Clinical Trial Shows Promise for Hepatitis B TreatmentNovember 17, 2024 | msn.comArbutus Biopharma’s Promising cHBV Treatment ResultsNovember 16, 2024 | markets.businessinsider.comArbutus Biopharma’s Trial Boosts Hepatitis B TreatmentNovember 16, 2024 | markets.businessinsider.comArbutus Biopharma to Showcase Innovations at Jefferies London Healthcare ConferenceNovember 16, 2024 | msn.comArbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Down 16.0% in OctoberArbutus Biopharma Co. (NASDAQ:ABUS - Get Free Report) was the target of a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 6,540,000 shares, a drop of 16.0% from the October 15th total of 7,790,000 shares. Based on an average trading volume of 1,100,000 shares, the days-to-cover ratio is currently 5.9 days.November 16, 2024 | marketbeat.comArbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of InterferonNovember 15, 2024 | markets.businessinsider.comArbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of InterferonNovember 15, 2024 | globenewswire.comArbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis BNovember 15, 2024 | globenewswire.comArbutus Biopharma to Present at Jefferies ConferenceNovember 15, 2024 | markets.businessinsider.comArbutus to Present at Jefferies London Healthcare ConferenceNovember 14, 2024 | globenewswire.comArbutus Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 14, 2024 | theglobeandmail.comHC Wainwright Expects Weaker Earnings for Arbutus BiopharmaArbutus Biopharma Co. (NASDAQ:ABUS - Free Report) - Stock analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for shares of Arbutus Biopharma in a note issued to investors on Thursday, November 7th. HC Wainwright analyst E. Arce now forecasts that the biopharmaceutNovember 11, 2024 | marketbeat.comArbutus Biopharma Advances Clinical Trials and Strengthens Financial Position in Q3 2024November 9, 2024 | msn.comArbutus Biopharma’s Promise and Risks: A Hold Rating Amid Early Trial Success and Legal UncertaintyNovember 9, 2024 | markets.businessinsider.comPromising Potential of Arbutus Biopharma’s Imdusiran in Achieving Functional Cure for Hepatitis B: Ed Arce’s Buy RatingNovember 7, 2024 | markets.businessinsider.comArbutus Biopharma (NASDAQ:ABUS) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $5.00 price objective on shares of Arbutus Biopharma in a research note on Thursday.November 7, 2024 | marketbeat.comQ3 2024 Arbutus Biopharma Corp Earnings CallNovember 7, 2024 | finance.yahoo.comArbutus Fades on Q4 ResultsNovember 7, 2024 | baystreet.caPromising Developments in Arbutus Biopharma’s Pipeline Lead to Buy Rating and Increased Price TargetNovember 7, 2024 | markets.businessinsider.comArbutus Biopharma’s Promising Clinical Developments and Strong Financial Position Justify Buy RatingNovember 7, 2024 | markets.businessinsider.comArbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ...November 7, 2024 | finance.yahoo.comArbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | seekingalpha.comArbutus Biopharma Corp.November 5, 2024 | wsj.comArbutus Biopharma (ABUS) Set to Announce Quarterly Earnings on WednesdayArbutus Biopharma (NASDAQ:ABUS) will be releasing earnings before the market opens on Wednesday, November 6, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=638746)October 30, 2024 | marketbeat.comArbutus Biopharma Set to Reveal Q3 2024 Results: Save the Date!October 25, 2024 | msn.comArbutus Biopharma to Announce Q3 2024 ResultsOctober 24, 2024 | markets.businessinsider.comArbutus to Report Third Quarter 2024 Financial Results and Provide Corporate UpdateOctober 23, 2024 | globenewswire.comArbutus Biopharma (NASDAQ:ABUS) Sees Strong Trading Volume - Still a Buy?Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume Increase - Should You Buy?October 16, 2024 | marketbeat.comArbutus Biopharma Target of Unusually High Options Trading (NASDAQ:ABUS)Arbutus Biopharma Co. (NASDAQ:ABUS - Get Free Report) was the recipient of unusually large options trading on Wednesday. Investors acquired 14,379 call options on the company. This is an increase of approximately 1,406% compared to the typical daily volume of 955 call options.October 16, 2024 | marketbeat.comArbutus Biopharma to Showcase Promising Imdusiran Data at Liver ConferenceOctober 16, 2024 | msn.comArbutus Biopharma (NASDAQ:ABUS) Trading Up 5.7% - Still a Buy?Arbutus Biopharma (NASDAQ:ABUS) Shares Up 5.7% - Here's What HappenedOctober 15, 2024 | marketbeat.comArbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024October 15, 2024 | globenewswire.comStrong Buy Rating for Arbutus Biopharma Amidst Promising CHB Treatment DevelopmentsOctober 11, 2024 | markets.businessinsider.com Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Secret Manhattan Project (Ad)On January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking. Click here and I’ll show you exactly how to position your money ABUS Media Mentions By Week ABUS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABUS News Sentiment▼1.510.72▲Average Medical News Sentiment ABUS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABUS Articles This Week▼23▲ABUS Articles Average Week Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DYN News CPRX News HCM News PTGX News AGIO News IOVA News AMRX News LBPH News NAMS News IDYA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABUS) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
